Quantcast

Latest Pseudomonas infection Stories

2009-03-24 08:44:04

Researchers at National Jewish Health have discovered a promising strategy for destroying the molecular scaffolding that can make Pseudomonas bacterial infections extremely difficult to treat in cystic fibrosis patients, wearers of contact lenses, and burn victims. Jerry Nick, MD, Associate Professor of Medicine at National Jewish Health, and his colleagues report in the April 2009 issue of The Journal of Medical Microbiology that a long string of aspartic acid molecules disrupts the...

2008-12-02 09:56:54

New clues about the most common cause of persistent and fatal lung infections in cystic fibrosis patients may lead to preventive treatments. A team of scientists at the University of Liverpool recently uncovered unique genetic features of the Liverpool Epidemic Strain, the most common strain of the deadly Pseudomonas aeruginosa bacteria infecting cystic fibrosis patients in the United Kingdom. They discovered some of the genes unique to the strain of bacteria are positioned in prophages,...

2008-10-03 09:00:07

Transave, a biopharmaceutical company, has secured a $12.5 million venture loan from CIT Healthcare and Compass Horizon Funding Company, an affiliate of Horizon Technology Finance Management. Transave has previously reported positive Phase II data on Arikace from a randomized, placebo-controlled, 15-center study conducted in Europe. The study demonstrated that Arikace, delivered once daily for 28 consecutive days using a novel inhalation device, an investigational eFlow nebulizer system...

2008-10-02 12:03:43

MONMOUTH JUNCTION, N.J., Oct. 2 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused on developing innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, today announced that it has secured a $12.5 million venture loan from CIT Healthcare and Compass Horizon Funding Company LLC, an affiliate of Horizon Technology Finance Management LLC. In June, Transave, Inc. reported positive Phase II data on Arikace(TM) (liposomal amikacin for...

2008-09-24 12:00:37

Canadian medical scientists say they have found a new treatment for severe lung infections caused by cystic fibrosis. Communities of bacteria grow in the lungs of people with CF, the scientists said, and Pseudomonas aeruginosa -- a common bacterium found in such communities -- represents a constant threat to the health of people with CF. Dr. Michael Surette, a professor of medicine at the University of Calgary, working with Dr. Harvey Rabin at the Calgary Adult CF Clinic, said they have...

2008-07-01 09:01:11

Aradigm has announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis. The primary efficacy endpoint in this Phase II study was the change from baseline in the sputum Pseudomonas Aeruginosa colony forming units (CFU), an objective measure of the reduction in pulmonary bacterial load. Data analysis in 21 patients who completed the study, demonstrated that the Pseudomonas CFU decreased...

2008-06-26 09:03:12

Mpex Pharmaceuticals has initiated a Phase II clinical study with MP-376 for the treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis. The Phase II, multi-center, international randomized, double-blind, placebo-controlled study (Mpex 204) is expected to enroll 140 stable cystic fibrosis (CF) patients to evaluate the safety, tolerability and efficacy of three dosage regimens of MP-376 given once or twice daily for 28 days. The...

2008-06-16 12:01:04

Gilead Sciences has announced positive results from an interim analysis of 12-month data from its open-label, Phase III AIR-CF3 study of aztreonam lysine for inhalation, an investigational therapy in development for the treatment of people with cystic fibrosis who have pulmonary Pseudomonas aeruginosa. In this analysis, 120 patients had reached the 12-month, six treatment course (28 days on and 28 days off) study milestone, with 48 patients in the twice-daily group and 72 patients in the...

8f45a90fcb2eb3888ebb5e6e474e70a61
2008-03-18 16:17:35

New U of T research holds promise for developing innovative therapies against cystic fibrosis and may also serve as a model for future therapies against the HIV virus. Led by Professor Igor Stagljar, University of Toronto scientists have identified several compounds that block activity of a key protein (exoenzymeS or ExoS). One of these compounds, exosin, significantly inhibited infections in mammalian cells, showing promise for increasing the effectiveness of antibiotics in the treatment of...

2005-06-02 14:49:39

Cells sent to fight infections in the lungs of cystic fibrosis patients actually enhance the development of permanent bacterial infections, according to researchers at National Jewish Medical and Research Center. Infections with the bacteria Pseudomonas are a major cause of sickness and death in cystic fibrosis patients. The findings, published in the June issue of Infection and Immunity, suggest new treatment strategies for patients with cystic fibrosis. "Pseudomonas can use the remnants of...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related